| 2024 | First-in-Human Phase 1 Study of a B Cell- and Monocyte-Based Immunotherapeutic Vaccine Against HER2-Positive Advanced Gastric Cancer
| CANCER RESEARCH AND TREATMENT |
| 2024 | Open-Label, Multicenter, Randomized, Biomarker-Integrated Umbrella Trial for Second-Line Treatment of Advanced Gastric Cancer: K-Umbrella Gastric Cancer Study | JOURNAL OF CLINICAL ONCOLOGY |
| 2024 | Second-line chemoimmunotherapy with nivolumab and paclitaxel in immune-related biomarker-enriched advanced gastric cancer: a multicenter phase Ib/II study | GASTRIC CANCER |
| 2024 | Durvalumab plus pazopanib combination in patients with advanced soft tissue sarcomas: a phase II trial
| NATURE COMMUNICATIONS |
| 2023 | Prior antibiotic administration disrupts anti-PD-1 responses in advanced gastric cancer by altering the gut microbiome and systemic immune response
| CELL REPORTS MEDICINE |
| 2023 | Impact of Coronavirus Disease 2019 on Gastric Cancer Diagnosis and Stage: A Single-Institute Study in South Korea
| JOURNAL OF GASTRIC CANCER |
| 2023 | Monitoring the Outcomes of Systemic Chemotherapy Including Immune Checkpoint Inhibitor for HER2-Positive Metastatic Gastric Cancer by Liquid Biopsy
| YONSEI MEDICAL JOURNAL |
| 2023 | Trastuzumab Combined With Ramucirumab and Paclitaxel in Patients With Previously Treated Human Epidermal Growth Factor Receptor 2–Positive Advanced Gastric or Gastroesophageal Junction Cancer | JOURNAL OF CLINICAL ONCOLOGY |
| 2023 | Comprehensive Molecular Characterization of Soft Tissue Sarcoma for Prediction of Pazopanib-Based Treatment Response
| CANCER RESEARCH AND TREATMENT |
| 2023 | Outcomes of an Acute Palliative Care Unit at a Comprehensive Cancer Center in Korea
| PALLIATIVE MEDICINE REPORTS |
| 2022 | Therapeutic Implications of TGF-β Pathway in Desmoid Tumor Based on Comprehensive Molecular Profiling and Clinicopathological Properties
| CANCERS |
| 2022 | A single arm phase Ib/II trial of first-line pembrolizumab, trastuzumab and chemotherapy for advanced HER2-positive gastric cancer
| NATURE COMMUNICATIONS |
| 2022 | First-in-human study of IM156, a novel potent biguanide oxidative phosphorylation (OXPHOS) inhibitor, in patients with advanced solid tumors
| INVESTIGATIONAL NEW DRUGS |
| 2022 | Whole-Genome and Transcriptome Sequencing Identified NOTCH2 and HES1 as Potential Markers of Response to Imatinib in Desmoid Tumor (Aggressive Fibromatosis): A Phase II Trial Study
| CANCER RESEARCH AND TREATMENT |
| 2022 | Hyperprogressive disease during PD-1 blockade in patients with advanced gastric cancer | EUROPEAN JOURNAL OF CANCER |
| 2022 | Phase II Clinical Trial of Eribulin-Gemcitabine Combination Therapy in Previously Treated Patients With Advanced Liposarcoma or Leiomyosarcoma | CLINICAL CANCER RESEARCH |
| 2022 | PD-L1 expression and overall survival in Asian and western patients with gastric cancer | FUTURE ONCOLOGY |
| 2022 | Tropomyosin-Related Kinase Fusions in Gastrointestinal Stromal Tumors
| CANCERS |
| 2022 | Cancer Therapy-Related Cardiac Dysfunction in Patients Treated with a Combination of an Immune Checkpoint Inhibitor and Doxorubicin
| CANCERS |
| 2022 | Multicenter phase Ib/II study of second-line trastuzumab, ramucirumab, and paclitaxel in patients with HER2-positive advanced gastric or gastroesophageal junction cancer: Updated HER-RAM study with biomarker analysis | JOURNAL OF CLINICAL ONCOLOGY |
| 2022 | Genomic profiling as a response predictor of second-line treatment in advanced gastric cancer patients: Post-hoc analyses of two phase Ib/II trials | JOURNAL OF CLINICAL ONCOLOGY |
| 2022 | Development and validation of a prognostic and predictive 32-gene signature for gastric cancer
| NATURE COMMUNICATIONS |
| 2022 | Recommendations for the Use of Next-Generation Sequencing and the Molecular Tumor Board for Patients with Advanced Cancer: A Report from KSMO and KCSG Precision Medicine Networking Group
| CANCER RESEARCH AND TREATMENT |
| 2021 | Prognostic significance of T-cell-inflamed gene expression profile and PD-L1 expression in patients with esophageal cancer
| CANCER MEDICINE |
| 2021 | Pemetrexed plus cisplatin in patients with previously treated advanced sarcoma: a multicenter, single-arm, phase II trial
| ESMO OPEN |
| 2021 | Detection of asymptomatic recurrence improves survival of gastric cancer patients
| CANCER MEDICINE |
| 2021 | Clinicopathological features of 70 desmoid-type fibromatoses confirmed by β-catenin immunohistochemical staining and CTNNB1 mutation analysis
| PLOS ONE |
| 2021 | Prognostic implications of PD-L1 expression in patients with angiosarcoma
| FUTURE SCIENCE OA |
| 2021 | PD-L1 tumour expression is predictive of pazopanib response in soft tissue sarcoma
| BMC CANCER |
| 2020 | Phase 2 study of afatinib among patients with recurrent and/or metastatic esophageal squamous cell carcinoma | CANCER |
| 2020 | Comprehensive Immuno-Molecular Profiles for Liposarcoma: Roles of Programmed Death Ligand 1, Microsatellite Instability, and PIK3CA | ONCOLOGY |
| 2020 | Real-World Outcomes of Pazopanib Treatment in Korean Patients with Advanced Soft Tissue Sarcoma: A Multicenter Retrospective Cohort Study | TARGETED ONCOLOGY |
| 2020 | Mass-forming ischemic colitis that mimics colon cancer
| CHINESE MEDICAL JOURNAL |
| 2019 | Randomised phase II trial comparing four front-line doublets in Asian patients with metastatic gastric cancer | EUROPEAN JOURNAL OF CANCER |
| 2019 | Inhibiting casein kinase 2 overcomes paclitaxel resistance in gastric cancer | GASTRIC CANCER |
| 2019 | Comprehensive immune profiling and immune-monitoring using body fluid of patients with metastatic gastric cancer
| Journal for Immunotherapy of Cancer |
| 2019 | Characteristics and Treatment Patterns of Patients with Advanced Soft Tissue Sarcoma in Korea
| CANCER RESEARCH AND TREATMENT |
| 2019 | Differences in the Efficacies of Pazopanib and Gemcitabine/Docetaxel as Second-Line Treatments for Metastatic Soft Tissue Sarcoma | Oncology |
| 2019 | Immunohistochemistry Biomarkers Predict Survival in Stage II/III Gastric Cancer Patients: From a Prospective Clinical Trial
| Cancer Research and Treatment |
| 2019 | Phase II trial of preoperative sequential chemotherapy followed by chemoradiotherapy for high-risk gastric cancer | RADIOTHERAPY AND ONCOLOGY |
| 2019 | Clinicalanalysisofpatientswithskeletalmetastasisoflung cancer
| BMC CANCER |
| 2019 | S-1 Based Doublet as an Adjuvant Chemotherapy for Curatively Resected Stage III Gastric Cancer: Results from the Randomized Phase III POST Trial
| CANCER RESEARCH AND TREATMENT |
| 2018 | A phase I/Ib study of OTSGC-A24 combined peptide vaccine in advanced gastric cancer
| BMC CANCER |
| 2018 | Multidisciplinary treatment for patients with stage IV gastric cancer: the role of conversion surgery following chemotherapy
| BMC CANCER |
| 2018 | Real-Time Tumor Gene Expression Profiling to Direct Gastric Cancer Chemotherapy: Proof-of-Concept "3G" Trial | CLINICAL CANCER RESEARCH |
| 2018 | Efficacy of Postoperative Radiotherapy Using Modern Techniques in Patients with Retroperitoneal Soft Tissue Sarcoma.
| YONSEI MEDICAL JOURNAL |
| 2018 | Marked Loss of Muscle, Visceral Fat, or Subcutaneous Fat After Gastrectomy Predicts Poor Survival in Advanced Gastric Cancer: Single-Center Study from the CLASSIC Trial | ANNALS OF SURGICAL ONCOLOGY |
| 2018 | A Prediction Model of Tumor Progression and Survival in HER2-Positive Metastatic Gastric Cancer Patients Treated with Trastuzumab and Chemotherapy | AAPS JOURNAL |
| 2018 | Prognostic significance of preoperative CT findings in patients with advanced gastric cancer who underwent curative gastrectomy
| PLOS ONE |
| 2018 | The prognostic value of volume-based parameters using<sup>18</sup>F-FDG PET/CT in gastric cancer according to HER2 status | GASTRIC CANCER |
http://orcid.org/0000-0002-0625-9828
(8709524100)
